[{"id":"d967b5ae-d88b-4ec0-a06f-cb86153c285e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07133685","created_at":"2025-08-23T13:29:45.512Z","updated_at":"2025-08-23T13:29:45.512Z","phase":"","brief_title":"Evaluation of Serum IL-7 as a Biomarker in Breast Cancer","source_id_and_acronym":"NCT07133685","lead_sponsor":"Assiut University","biomarkers":" IL7","pipe":"","alterations":" ","tags":["IL7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-08-21"},{"id":"e3758902-bfaa-4750-9720-e72a30a02467","acronym":"mCRC-POET","url":"https://clinicaltrials.gov/study/NCT05579340","created_at":"2022-10-13T16:56:38.502Z","updated_at":"2024-07-02T16:35:49.282Z","phase":"","brief_title":"Postoperative Exercise Training and Colorectal Cancer Liver Metastasis","source_id_and_acronym":"NCT05579340 - mCRC-POET","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" CD8 • IFNG • IL6 • TNFA • CD4 • IL10 • IL15 • IL7 • CRP","pipe":" | ","alterations":" IL10 elevation","tags":["CD8 • IFNG • IL6 • TNFA • CD4 • IL10 • IL15 • IL7 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-05-01"},{"id":"398611ec-32d5-4767-9ab0-d167a02f0c96","acronym":"ICE","url":"https://clinicaltrials.gov/study/NCT05727813","created_at":"2023-02-14T18:02:36.078Z","updated_at":"2024-07-02T16:35:55.606Z","phase":"","brief_title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","source_id_and_acronym":"NCT05727813 - ICE","lead_sponsor":"University of Roma La Sapienza","biomarkers":" IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 01/27/2023","study_completion_date":" 01/27/2023","last_update_posted":"2023-02-14"},{"id":"8e400406-6f6a-4f41-824d-61725c09b480","acronym":"CICPD","url":"https://clinicaltrials.gov/study/NCT04381741","created_at":"2021-01-18T21:09:36.209Z","updated_at":"2024-07-02T16:35:56.413Z","phase":"Phase 1","brief_title":"CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04381741 - CICPD","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD20 • CD19 • PD-1 • CCL19 • IL7","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19 • PD-1 • CCL19 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • CD19-7×19 CAR-T"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 24","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-06"},{"id":"00b653d7-12d2-4c0a-ad1f-a20655e5ffda","acronym":"","url":"https://clinicaltrials.gov/study/NCT01165645","created_at":"2021-01-18T04:38:52.857Z","updated_at":"2024-07-02T16:35:59.786Z","phase":"","brief_title":"Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma","source_id_and_acronym":"NCT01165645","lead_sponsor":"Mayo Clinic","biomarkers":" CD8 • IL6 • TNFA • CXCL8 • CD4 • IL2 • IL10 • IL4 • IL7","pipe":"","alterations":" ","tags":["CD8 • IL6 • TNFA • CXCL8 • CD4 • IL2 • IL10 • IL4 • IL7"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 12/14/2011","study_completion_date":" 12/14/2011","last_update_posted":"2022-12-01"},{"id":"024e1277-d133-4914-a627-57cfe108a970","acronym":"TruCulture","url":"https://clinicaltrials.gov/study/NCT04127864","created_at":"2021-01-18T20:09:51.316Z","updated_at":"2024-07-02T16:36:05.964Z","phase":"","brief_title":"Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery","source_id_and_acronym":"NCT04127864 - TruCulture","lead_sponsor":"University of Copenhagen","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-08-05"},{"id":"9c144da4-4e9a-42e5-b067-fb9a8c215f91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05300412","created_at":"2022-03-29T12:53:21.208Z","updated_at":"2024-07-02T16:36:14.508Z","phase":"","brief_title":"The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer","source_id_and_acronym":"NCT05300412","lead_sponsor":"University Clinical Centre of Kosova","biomarkers":" HER-2 • PGR • IL7","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2 • PGR • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 09/10/2019","primary_completion_date":" 09/10/2019","study_txt":" Completion: 12/20/2019","study_completion_date":" 12/20/2019","last_update_posted":"2022-03-29"},{"id":"4b8b6532-0cca-44de-a7cf-fda3307838db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00099671","created_at":"2021-01-18T00:18:59.332Z","updated_at":"2024-07-02T16:36:21.786Z","phase":"Phase 1","brief_title":"Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs","source_id_and_acronym":"NCT00099671","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4 • IL7","pipe":"","alterations":" ","tags":["CD4 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2005","start_date":" 04/01/2005","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 04/01/2007","study_completion_date":" 04/01/2007","last_update_posted":"2021-11-01"},{"id":"36dae252-34db-4379-9046-72e155c4512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04833504","created_at":"2021-04-06T11:55:29.016Z","updated_at":"2024-07-02T16:36:32.311Z","phase":"","brief_title":"Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04833504","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CCL19 • IL7","pipe":"","alterations":" ","tags":["CCL19 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19-7×19 CAR-T"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2021-04-06"},{"id":"c1c8a21f-267f-4773-bc59-4b9d7ab6b8c3","acronym":"GBM","url":"https://clinicaltrials.gov/study/NCT03619239","created_at":"2021-01-18T17:47:07.454Z","updated_at":"2024-07-02T16:36:38.902Z","phase":"Phase 1b","brief_title":"Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma","source_id_and_acronym":"NCT03619239 - GBM","lead_sponsor":"Genexine, Inc.","biomarkers":" IL7","pipe":"","alterations":" ","tags":["IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hyleukin-7 (efineptakin alfa)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 09/25/2020","primary_completion_date":" 09/25/2020","study_txt":" Completion: 09/25/2020","study_completion_date":" 09/25/2020","last_update_posted":"2020-11-10"},{"id":"66e0fc5a-b053-47ce-b084-660c0c6c06be","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696056","created_at":"2021-01-18T18:06:55.792Z","updated_at":"2024-07-02T16:36:38.964Z","phase":"","brief_title":"Improving Brain Function After Breast Cancer Study","source_id_and_acronym":"NCT03696056","lead_sponsor":"University of Texas at Austin","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/30/2020","study_completion_date":" 01/30/2020","last_update_posted":"2020-11-09"},{"id":"ef7264fb-6d3e-46dd-8666-931cd794a677","acronym":"","url":"https://clinicaltrials.gov/study/NCT00013533","created_at":"2021-01-17T23:55:41.070Z","updated_at":"2024-07-02T16:36:52.446Z","phase":"Phase 1","brief_title":"Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies","source_id_and_acronym":"NCT00013533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL7","pipe":"","alterations":" ","tags":["IL7"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/14/2001","start_date":" 03/14/2001","primary_txt":" Primary completion: 03/01/2008","primary_completion_date":" 03/01/2008","study_txt":" Completion: 05/07/2015","study_completion_date":" 05/07/2015","last_update_posted":"2019-12-16"},{"id":"c16de0cf-b9fe-4442-8cd2-246fe6771da8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01287104","created_at":"2021-01-18T05:13:27.987Z","updated_at":"2024-07-02T16:36:56.638Z","phase":"Phase 1","brief_title":"A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias","source_id_and_acronym":"NCT01287104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)","tags":["FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/29/2011","start_date":" 01/29/2011","primary_txt":" Primary completion: 06/28/2018","primary_completion_date":" 06/28/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-08-22"},{"id":"9c5e4e1e-d50a-4f40-aa00-425ef29cbd1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00520130","created_at":"2021-01-18T01:52:41.568Z","updated_at":"2024-07-02T16:37:02.230Z","phase":"Phase 2","brief_title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","source_id_and_acronym":"NCT00520130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • CCR7 • IL7","pipe":"","alterations":" ","tags":["CD8 • CD4 • CCR7 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • sirolimus • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 10/30/2007","start_date":" 10/30/2007","primary_txt":" Primary completion: 10/14/2015","primary_completion_date":" 10/14/2015","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2019-03-05"},{"id":"fe483aa4-fb68-4ecb-afc4-66f383238c79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02466061","created_at":"2021-01-18T11:52:10.923Z","updated_at":"2024-07-02T16:37:31.541Z","phase":"","brief_title":"TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors","source_id_and_acronym":"NCT02466061","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL6 • CXCL8 • IL2 • IL1B • IL7 • IGFBP1","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL1B • IL7 • IGFBP1"],"overall_status":"Completed","enrollment":" Enrollment 207","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2016-06-02"}]